CoChat
Sign Up
Cited by 1,271Alcohol Consumption and Health EffectsLiver Disease Diagnosis and TreatmentLiver Disease and Transplantation

The DOI matches its Crossref record; 242 of the 244 references it cites were found in a registry or an index.

Alcoholic liver disease

Seitz, Helmut K., Bataller, Ramon, Cortez-Pinto, Helena, Gao, Bin, Gual, Antoni, Lackner, Carolin, Mathurin, Philippe, Mueller, Sebastian, Szabo, Gyongyi, Tsukamoto, Hidekazu·2018·Nature Reviews Disease Primers
DOI 10.1038/s41572-018-0014-7
Open this paper in CoChat — free account

Abstract

Alcoholic liver disease (ALD) is the most prevalent type of chronic liver disease worldwide. ALD can progress from alcoholic fatty liver (AFL) to alcoholic steatohepatitis (ASH), which is characterized by hepatic inflammation. Chronic ASH can eventually lead to fibrosis and cirrhosis and in some cases hepatocellular cancer (HCC). In addition, severe ASH (with or without cirrhosis) can lead to alcoholic hepatitis, which is an acute clinical presentation of ALD that is associated with liver failure and high mortality. Most individuals consuming >40 g of alcohol per day develop AFL; however, only a subset of individuals will develop more advanced disease. Genetic, epigenetic and non-genetic factors might explain the considerable interindividual variation in ALD phenotype. The pathogenesis of ALD includes hepatic steatosis, oxidative stress, acetaldehyde-mediated toxicity and cytokine and chemokine-induced inflammation. Diagnosis of ALD involves assessing patients for alcohol use disorder and signs of advanced liver disease. The degree of AFL and liver fibrosis can be determined by ultrasonography, transient elastography, MRI, measurement of serum biomarkers and liver biopsy histology. Alcohol abstinence achieved by psychosomatic intervention is the best treatment for all stages of ALD. In the case of advanced disease such as cirrhosis or HCC, liver transplantation may be required. Thus, new therapies are urgently needed.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41572-018-0014-7

Cites

242 of 242 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 244 references

Research works printed but not linked: 4

  1. Pone, E. J. Toll-like receptors. Signal. Pathways Liver Diseases 1390, 149–159 (2016).
  2. French, S. W. & Bardag-Gorce, F. in Signaling Pathways in Liver Diseases (eds Dufour, J.-F. et al.) 377–389 (Springer, 2005).
  3. Thiele, M. et al. Controlled attenuation parameter and alcoholic hepatic steatosis: diagnostic accuracy and role of alcohol detoxification. J. Hepatol. 68, 1025–1032 (2018). · DOI
  4. [No authors listed.]. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1, 707–711 (1981).

Cited by

Sorted by citations

Items 901–999 of 999

Related

See all

Metadata

Authors
Seitz, H. K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., & Tsukamoto, H.
Affiliations
  • Heidelberg University (DE)
  • University of Pittsburgh (US)
  • National Institutes of Health (US)
  • Hospital Clínic de Barcelona (ES)
  • Medical University of Graz (AT)
  • Inserm (FR)
  • University of Southern California (US)
ORCID
Venue
Nature Reviews Disease Primers
Publisher
Springer Science and Business Media LLC
Published
2018-08-16
Volume
4
Issue
1
Pages
16-16
ISSN
2056-676X (ISSN-L)
DOI
10.1038/s41572-018-0014-7
OpenAlex
W4210980460
Cited by
1,271
References
244
Citations by year
2026: 126 · 2025: 200 · 2024: 249 · 2023: 230 · 2022: 176 · 2021: 145 · 2020: 75 · 2019: 57 · 2018: 9
FWCI
10.57
Type
journal article
Language
en
Update notices
correction (2018-08-28)
Open access
closed
Licence
Locations
  • Nature Reviews Disease Primers (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • U.S. Department of Veterans Affairs (IK6BX004205, I01 BX001991)
  • National Institute on Alcohol Abuse and Alcoholism (R01AA011576)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
alcoholic liver disease, alcoholic fatty liver, alcoholic steatohepatitis, alcoholic hepatitis, liver cirrhosis, hepatocellular carcinoma, liver fibrosis, hepatic steatosis, oxidative stress, acetaldehyde toxicity, liver inflammation, alcoholism, liver fibrosis diagnosis, serum biomarkers, alcohol abstinence, liver transplantation
MeSH terms
Global Burden of Disease, Alcohol Drinking, Fatty Liver, Alcoholic, Humans, Liver Diseases, Alcoholic, Liver Neoplasms, Quality of Life, Liver Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review